nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosinopril—ACE—Metabolism of Angiotensinogen to Angiotensins—ANPEP—hematologic cancer	0.00998	0.158	CbGpPWpGaD
Fosinopril—ACE—Metabolism of Angiotensinogen to Angiotensins—CTSZ—hematologic cancer	0.00998	0.158	CbGpPWpGaD
Fosinopril—ACE—Metabolism of Angiotensinogen to Angiotensins—MME—hematologic cancer	0.00493	0.0781	CbGpPWpGaD
Fosinopril—ACE—Metabolism of Angiotensinogen to Angiotensins—CMA1—hematologic cancer	0.00487	0.0772	CbGpPWpGaD
Fosinopril—ACE—ACE Inhibitor Pathway—CMA1—hematologic cancer	0.00464	0.0735	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—ANPEP—hematologic cancer	0.00262	0.0415	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—CTSZ—hematologic cancer	0.00262	0.0415	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—MME—hematologic cancer	0.0013	0.0205	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—CMA1—hematologic cancer	0.00128	0.0203	CbGpPWpGaD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—hematologic cancer	0.00101	0.016	CbGpPWpGaD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—hematologic cancer	0.000939	0.0149	CbGpPWpGaD
Fosinopril—ACE—ACE Inhibitor Pathway—TGFB1—hematologic cancer	0.000934	0.0148	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—LDHD—hematologic cancer	0.000768	0.0122	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—GCNT4—hematologic cancer	0.000582	0.00923	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000507	0.00803	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—CTSZ—hematologic cancer	0.000495	0.00784	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—ANPEP—hematologic cancer	0.000495	0.00784	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000471	0.00746	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—DPM1—hematologic cancer	0.000466	0.00738	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—ASNS—hematologic cancer	0.000466	0.00738	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000452	0.00716	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—PREB—hematologic cancer	0.000421	0.00667	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000419	0.00665	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—GCNT1—hematologic cancer	0.000404	0.00639	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000366	0.00579	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—MUC1—hematologic cancer	0.000343	0.00544	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.00034	0.00539	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000339	0.00538	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.000316	0.005	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—RPLP1—hematologic cancer	0.0003	0.00475	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	0.000299	0.00474	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—NUP98—hematologic cancer	0.000282	0.00447	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	0.000277	0.00439	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000277	0.00439	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—TUBB2A—hematologic cancer	0.000275	0.00436	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—NUP214—hematologic cancer	0.000272	0.00431	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—NUP98—hematologic cancer	0.000262	0.00415	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000258	0.00408	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000257	0.00408	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—NUP214—hematologic cancer	0.000252	0.004	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—MME—hematologic cancer	0.000245	0.00387	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000242	0.00384	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—SUMO1—hematologic cancer	0.000242	0.00383	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—CMA1—hematologic cancer	0.000242	0.00383	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000239	0.00379	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—SPHK1—hematologic cancer	0.000237	0.00375	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.00023	0.00364	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000225	0.00356	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000213	0.00338	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—RPS14—hematologic cancer	0.000212	0.00336	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.00021	0.00333	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.00021	0.00333	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.00021	0.00333	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000195	0.00309	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000195	0.00309	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000195	0.00309	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000189	0.003	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—EIF4EBP1—hematologic cancer	0.000185	0.00294	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000176	0.00278	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—HSPA5—hematologic cancer	0.000171	0.00272	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—CALR—hematologic cancer	0.000166	0.00263	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000166	0.00263	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—FBXW7—hematologic cancer	0.000161	0.00255	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000154	0.00244	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	0.000152	0.00241	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—NUP98—hematologic cancer	0.000143	0.00227	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	0.000141	0.00223	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ADCY7—hematologic cancer	0.000139	0.0022	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—NUP214—hematologic cancer	0.000138	0.00219	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ABCG2—hematologic cancer	0.000135	0.00214	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—NUP98—hematologic cancer	0.000133	0.00211	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	0.000129	0.00205	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—NUP214—hematologic cancer	0.000128	0.00203	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	0.000126	0.00199	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—TFRC—hematologic cancer	0.000121	0.00191	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—TFRC—hematologic cancer	0.000112	0.00177	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—ALB—hematologic cancer	0.000104	0.00165	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—CYCS—hematologic cancer	0.000101	0.0016	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—ALB—hematologic cancer	9.65e-05	0.00153	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—CYCS—hematologic cancer	9.4e-05	0.00149	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	8.45e-05	0.00134	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—CCL2—hematologic cancer	8.26e-05	0.00131	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ABCB1—hematologic cancer	7.84e-05	0.00124	CbGpPWpGaD
Fosinopril—Infection—Prednisone—hematologic cancer	6.75e-05	7.2e-05	CcSEcCtD
Fosinopril—Fatigue—Betamethasone—hematologic cancer	6.72e-05	7.18e-05	CcSEcCtD
Fosinopril—Fatigue—Dexamethasone—hematologic cancer	6.72e-05	7.18e-05	CcSEcCtD
Fosinopril—Chills—Epirubicin—hematologic cancer	6.71e-05	7.16e-05	CcSEcCtD
Fosinopril—Pruritus—Etoposide—hematologic cancer	6.7e-05	7.16e-05	CcSEcCtD
Fosinopril—Shock—Prednisone—hematologic cancer	6.68e-05	7.13e-05	CcSEcCtD
Fosinopril—Arrhythmia—Epirubicin—hematologic cancer	6.68e-05	7.13e-05	CcSEcCtD
Fosinopril—Pain—Dexamethasone—hematologic cancer	6.67e-05	7.12e-05	CcSEcCtD
Fosinopril—Pain—Betamethasone—hematologic cancer	6.67e-05	7.12e-05	CcSEcCtD
Fosinopril—Visual impairment—Doxorubicin—hematologic cancer	6.67e-05	7.12e-05	CcSEcCtD
Fosinopril—Tachycardia—Prednisone—hematologic cancer	6.63e-05	7.07e-05	CcSEcCtD
Fosinopril—Nausea—Gemcitabine—hematologic cancer	6.59e-05	7.04e-05	CcSEcCtD
Fosinopril—Vomiting—Cisplatin—hematologic cancer	6.58e-05	7.02e-05	CcSEcCtD
Fosinopril—Hyperhidrosis—Prednisone—hematologic cancer	6.57e-05	7.01e-05	CcSEcCtD
Fosinopril—Vision blurred—Methotrexate—hematologic cancer	6.55e-05	7e-05	CcSEcCtD
Fosinopril—Erythema multiforme—Doxorubicin—hematologic cancer	6.54e-05	6.98e-05	CcSEcCtD
Fosinopril—Rash—Cisplatin—hematologic cancer	6.52e-05	6.96e-05	CcSEcCtD
Fosinopril—Dermatitis—Cisplatin—hematologic cancer	6.52e-05	6.95e-05	CcSEcCtD
Fosinopril—Diarrhoea—Etoposide—hematologic cancer	6.48e-05	6.92e-05	CcSEcCtD
Fosinopril—Anorexia—Prednisone—hematologic cancer	6.47e-05	6.91e-05	CcSEcCtD
Fosinopril—Ill-defined disorder—Methotrexate—hematologic cancer	6.45e-05	6.89e-05	CcSEcCtD
Fosinopril—Tinnitus—Doxorubicin—hematologic cancer	6.45e-05	6.88e-05	CcSEcCtD
Fosinopril—Anaemia—Methotrexate—hematologic cancer	6.43e-05	6.86e-05	CcSEcCtD
Fosinopril—Feeling abnormal—Dexamethasone—hematologic cancer	6.43e-05	6.86e-05	CcSEcCtD
Fosinopril—Feeling abnormal—Betamethasone—hematologic cancer	6.43e-05	6.86e-05	CcSEcCtD
Fosinopril—Flushing—Doxorubicin—hematologic cancer	6.42e-05	6.85e-05	CcSEcCtD
Fosinopril—Flatulence—Epirubicin—hematologic cancer	6.41e-05	6.84e-05	CcSEcCtD
Fosinopril—Tension—Epirubicin—hematologic cancer	6.39e-05	6.82e-05	CcSEcCtD
Fosinopril—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.38e-05	6.81e-05	CcSEcCtD
Fosinopril—Gastrointestinal pain—Betamethasone—hematologic cancer	6.38e-05	6.81e-05	CcSEcCtD
Fosinopril—Dysgeusia—Epirubicin—hematologic cancer	6.37e-05	6.8e-05	CcSEcCtD
Fosinopril—Hypersensitivity—Triamcinolone—hematologic cancer	6.33e-05	6.76e-05	CcSEcCtD
Fosinopril—Nervousness—Epirubicin—hematologic cancer	6.32e-05	6.75e-05	CcSEcCtD
Fosinopril—Malaise—Methotrexate—hematologic cancer	6.27e-05	6.69e-05	CcSEcCtD
Fosinopril—Dizziness—Etoposide—hematologic cancer	6.27e-05	6.69e-05	CcSEcCtD
Fosinopril—Muscle spasms—Epirubicin—hematologic cancer	6.26e-05	6.68e-05	CcSEcCtD
Fosinopril—Vertigo—Methotrexate—hematologic cancer	6.25e-05	6.67e-05	CcSEcCtD
Fosinopril—Leukopenia—Methotrexate—hematologic cancer	6.22e-05	6.64e-05	CcSEcCtD
Fosinopril—Chills—Doxorubicin—hematologic cancer	6.21e-05	6.62e-05	CcSEcCtD
Fosinopril—Urticaria—Dexamethasone—hematologic cancer	6.19e-05	6.61e-05	CcSEcCtD
Fosinopril—Urticaria—Betamethasone—hematologic cancer	6.19e-05	6.61e-05	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.19e-05	6.6e-05	CcSEcCtD
Fosinopril—Dizziness—Prednisolone—hematologic cancer	6.18e-05	6.6e-05	CcSEcCtD
Fosinopril—Arrhythmia—Doxorubicin—hematologic cancer	6.18e-05	6.6e-05	CcSEcCtD
Fosinopril—Asthenia—Triamcinolone—hematologic cancer	6.17e-05	6.58e-05	CcSEcCtD
Fosinopril—Abdominal pain—Dexamethasone—hematologic cancer	6.16e-05	6.58e-05	CcSEcCtD
Fosinopril—Body temperature increased—Dexamethasone—hematologic cancer	6.16e-05	6.58e-05	CcSEcCtD
Fosinopril—Body temperature increased—Betamethasone—hematologic cancer	6.16e-05	6.58e-05	CcSEcCtD
Fosinopril—Abdominal pain—Betamethasone—hematologic cancer	6.16e-05	6.58e-05	CcSEcCtD
Fosinopril—Nausea—Cisplatin—hematologic cancer	6.14e-05	6.56e-05	CcSEcCtD
Fosinopril—Insomnia—Prednisone—hematologic cancer	6.14e-05	6.56e-05	CcSEcCtD
Fosinopril—Vision blurred—Epirubicin—hematologic cancer	6.13e-05	6.55e-05	CcSEcCtD
Fosinopril—Paraesthesia—Prednisone—hematologic cancer	6.1e-05	6.51e-05	CcSEcCtD
Fosinopril—Pruritus—Triamcinolone—hematologic cancer	6.08e-05	6.49e-05	CcSEcCtD
Fosinopril—Cough—Methotrexate—hematologic cancer	6.07e-05	6.48e-05	CcSEcCtD
Fosinopril—Ill-defined disorder—Epirubicin—hematologic cancer	6.04e-05	6.45e-05	CcSEcCtD
Fosinopril—Vomiting—Etoposide—hematologic cancer	6.02e-05	6.43e-05	CcSEcCtD
Fosinopril—Anaemia—Epirubicin—hematologic cancer	6.01e-05	6.42e-05	CcSEcCtD
Fosinopril—Agitation—Epirubicin—hematologic cancer	5.98e-05	6.38e-05	CcSEcCtD
Fosinopril—Dyspepsia—Prednisone—hematologic cancer	5.98e-05	6.38e-05	CcSEcCtD
Fosinopril—Rash—Etoposide—hematologic cancer	5.97e-05	6.38e-05	CcSEcCtD
Fosinopril—Dermatitis—Etoposide—hematologic cancer	5.97e-05	6.37e-05	CcSEcCtD
Fosinopril—Headache—Etoposide—hematologic cancer	5.94e-05	6.34e-05	CcSEcCtD
Fosinopril—Flatulence—Doxorubicin—hematologic cancer	5.93e-05	6.33e-05	CcSEcCtD
Fosinopril—Myalgia—Methotrexate—hematologic cancer	5.92e-05	6.32e-05	CcSEcCtD
Fosinopril—Arthralgia—Methotrexate—hematologic cancer	5.92e-05	6.32e-05	CcSEcCtD
Fosinopril—Chest pain—Methotrexate—hematologic cancer	5.92e-05	6.32e-05	CcSEcCtD
Fosinopril—Tension—Doxorubicin—hematologic cancer	5.91e-05	6.31e-05	CcSEcCtD
Fosinopril—Decreased appetite—Prednisone—hematologic cancer	5.9e-05	6.3e-05	CcSEcCtD
Fosinopril—Dysgeusia—Doxorubicin—hematologic cancer	5.9e-05	6.29e-05	CcSEcCtD
Fosinopril—Rash—Prednisolone—hematologic cancer	5.89e-05	6.29e-05	CcSEcCtD
Fosinopril—Dermatitis—Prednisolone—hematologic cancer	5.89e-05	6.28e-05	CcSEcCtD
Fosinopril—Malaise—Epirubicin—hematologic cancer	5.87e-05	6.26e-05	CcSEcCtD
Fosinopril—Fatigue—Prednisone—hematologic cancer	5.85e-05	6.25e-05	CcSEcCtD
Fosinopril—Headache—Prednisolone—hematologic cancer	5.85e-05	6.25e-05	CcSEcCtD
Fosinopril—Discomfort—Methotrexate—hematologic cancer	5.85e-05	6.24e-05	CcSEcCtD
Fosinopril—Nervousness—Doxorubicin—hematologic cancer	5.85e-05	6.24e-05	CcSEcCtD
Fosinopril—Vertigo—Epirubicin—hematologic cancer	5.85e-05	6.24e-05	CcSEcCtD
Fosinopril—Syncope—Epirubicin—hematologic cancer	5.84e-05	6.23e-05	CcSEcCtD
Fosinopril—Leukopenia—Epirubicin—hematologic cancer	5.83e-05	6.22e-05	CcSEcCtD
Fosinopril—Constipation—Prednisone—hematologic cancer	5.81e-05	6.2e-05	CcSEcCtD
Fosinopril—Muscle spasms—Doxorubicin—hematologic cancer	5.79e-05	6.18e-05	CcSEcCtD
Fosinopril—Palpitations—Epirubicin—hematologic cancer	5.75e-05	6.14e-05	CcSEcCtD
Fosinopril—Confusional state—Methotrexate—hematologic cancer	5.72e-05	6.11e-05	CcSEcCtD
Fosinopril—Loss of consciousness—Epirubicin—hematologic cancer	5.72e-05	6.11e-05	CcSEcCtD
Fosinopril—Dizziness—Triamcinolone—hematologic cancer	5.68e-05	6.07e-05	CcSEcCtD
Fosinopril—Cough—Epirubicin—hematologic cancer	5.68e-05	6.06e-05	CcSEcCtD
Fosinopril—Anaphylactic shock—Methotrexate—hematologic cancer	5.68e-05	6.06e-05	CcSEcCtD
Fosinopril—Vision blurred—Doxorubicin—hematologic cancer	5.67e-05	6.06e-05	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.65e-05	0.000895	CbGpPWpGaD
Fosinopril—Infection—Methotrexate—hematologic cancer	5.64e-05	6.02e-05	CcSEcCtD
Fosinopril—Nausea—Etoposide—hematologic cancer	5.63e-05	6.01e-05	CcSEcCtD
Fosinopril—Hypertension—Epirubicin—hematologic cancer	5.62e-05	6e-05	CcSEcCtD
Fosinopril—Feeling abnormal—Prednisone—hematologic cancer	5.6e-05	5.97e-05	CcSEcCtD
Fosinopril—Asthenia—Dexamethasone—hematologic cancer	5.59e-05	5.97e-05	CcSEcCtD
Fosinopril—Asthenia—Betamethasone—hematologic cancer	5.59e-05	5.97e-05	CcSEcCtD
Fosinopril—Ill-defined disorder—Doxorubicin—hematologic cancer	5.59e-05	5.96e-05	CcSEcCtD
Fosinopril—Anaemia—Doxorubicin—hematologic cancer	5.57e-05	5.94e-05	CcSEcCtD
Fosinopril—Thrombocytopenia—Methotrexate—hematologic cancer	5.56e-05	5.93e-05	CcSEcCtD
Fosinopril—Gastrointestinal pain—Prednisone—hematologic cancer	5.55e-05	5.93e-05	CcSEcCtD
Fosinopril—Nausea—Prednisolone—hematologic cancer	5.55e-05	5.93e-05	CcSEcCtD
Fosinopril—Myalgia—Epirubicin—hematologic cancer	5.54e-05	5.91e-05	CcSEcCtD
Fosinopril—Arthralgia—Epirubicin—hematologic cancer	5.54e-05	5.91e-05	CcSEcCtD
Fosinopril—Chest pain—Epirubicin—hematologic cancer	5.54e-05	5.91e-05	CcSEcCtD
Fosinopril—Agitation—Doxorubicin—hematologic cancer	5.53e-05	5.91e-05	CcSEcCtD
Fosinopril—Pruritus—Dexamethasone—hematologic cancer	5.52e-05	5.89e-05	CcSEcCtD
Fosinopril—Pruritus—Betamethasone—hematologic cancer	5.52e-05	5.89e-05	CcSEcCtD
Fosinopril—Hyperhidrosis—Methotrexate—hematologic cancer	5.49e-05	5.86e-05	CcSEcCtD
Fosinopril—Discomfort—Epirubicin—hematologic cancer	5.47e-05	5.84e-05	CcSEcCtD
Fosinopril—Vomiting—Triamcinolone—hematologic cancer	5.46e-05	5.83e-05	CcSEcCtD
Fosinopril—Malaise—Doxorubicin—hematologic cancer	5.43e-05	5.8e-05	CcSEcCtD
Fosinopril—Rash—Triamcinolone—hematologic cancer	5.42e-05	5.78e-05	CcSEcCtD
Fosinopril—Dry mouth—Epirubicin—hematologic cancer	5.42e-05	5.78e-05	CcSEcCtD
Fosinopril—Dermatitis—Triamcinolone—hematologic cancer	5.41e-05	5.78e-05	CcSEcCtD
Fosinopril—Vertigo—Doxorubicin—hematologic cancer	5.41e-05	5.77e-05	CcSEcCtD
Fosinopril—Anorexia—Methotrexate—hematologic cancer	5.41e-05	5.77e-05	CcSEcCtD
Fosinopril—Syncope—Doxorubicin—hematologic cancer	5.4e-05	5.76e-05	CcSEcCtD
Fosinopril—Urticaria—Prednisone—hematologic cancer	5.39e-05	5.76e-05	CcSEcCtD
Fosinopril—Leukopenia—Doxorubicin—hematologic cancer	5.39e-05	5.75e-05	CcSEcCtD
Fosinopril—Headache—Triamcinolone—hematologic cancer	5.38e-05	5.75e-05	CcSEcCtD
Fosinopril—Abdominal pain—Prednisone—hematologic cancer	5.37e-05	5.73e-05	CcSEcCtD
Fosinopril—Body temperature increased—Prednisone—hematologic cancer	5.37e-05	5.73e-05	CcSEcCtD
Fosinopril—Confusional state—Epirubicin—hematologic cancer	5.36e-05	5.72e-05	CcSEcCtD
Fosinopril—Diarrhoea—Dexamethasone—hematologic cancer	5.34e-05	5.69e-05	CcSEcCtD
Fosinopril—Diarrhoea—Betamethasone—hematologic cancer	5.34e-05	5.69e-05	CcSEcCtD
Fosinopril—Palpitations—Doxorubicin—hematologic cancer	5.32e-05	5.68e-05	CcSEcCtD
Fosinopril—Oedema—Epirubicin—hematologic cancer	5.31e-05	5.67e-05	CcSEcCtD
Fosinopril—Anaphylactic shock—Epirubicin—hematologic cancer	5.31e-05	5.67e-05	CcSEcCtD
Fosinopril—Hypotension—Methotrexate—hematologic cancer	5.3e-05	5.66e-05	CcSEcCtD
Fosinopril—Loss of consciousness—Doxorubicin—hematologic cancer	5.29e-05	5.65e-05	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ALB—hematologic cancer	5.29e-05	0.000837	CbGpPWpGaD
Fosinopril—Infection—Epirubicin—hematologic cancer	5.28e-05	5.63e-05	CcSEcCtD
Fosinopril—Cough—Doxorubicin—hematologic cancer	5.25e-05	5.61e-05	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	5.24e-05	0.00083	CbGpPWpGaD
Fosinopril—Shock—Epirubicin—hematologic cancer	5.23e-05	5.58e-05	CcSEcCtD
Fosinopril—Thrombocytopenia—Epirubicin—hematologic cancer	5.2e-05	5.55e-05	CcSEcCtD
Fosinopril—Hypertension—Doxorubicin—hematologic cancer	5.2e-05	5.55e-05	CcSEcCtD
Fosinopril—Tachycardia—Epirubicin—hematologic cancer	5.18e-05	5.53e-05	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.17e-05	5.52e-05	CcSEcCtD
Fosinopril—Dizziness—Betamethasone—hematologic cancer	5.16e-05	5.5e-05	CcSEcCtD
Fosinopril—Dizziness—Dexamethasone—hematologic cancer	5.16e-05	5.5e-05	CcSEcCtD
Fosinopril—Hyperhidrosis—Epirubicin—hematologic cancer	5.13e-05	5.48e-05	CcSEcCtD
Fosinopril—Insomnia—Methotrexate—hematologic cancer	5.13e-05	5.48e-05	CcSEcCtD
Fosinopril—Myalgia—Doxorubicin—hematologic cancer	5.13e-05	5.47e-05	CcSEcCtD
Fosinopril—Chest pain—Doxorubicin—hematologic cancer	5.13e-05	5.47e-05	CcSEcCtD
Fosinopril—Arthralgia—Doxorubicin—hematologic cancer	5.13e-05	5.47e-05	CcSEcCtD
Fosinopril—Nausea—Triamcinolone—hematologic cancer	5.1e-05	5.45e-05	CcSEcCtD
Fosinopril—Paraesthesia—Methotrexate—hematologic cancer	5.1e-05	5.44e-05	CcSEcCtD
Fosinopril—Discomfort—Doxorubicin—hematologic cancer	5.07e-05	5.41e-05	CcSEcCtD
Fosinopril—Anorexia—Epirubicin—hematologic cancer	5.06e-05	5.4e-05	CcSEcCtD
Fosinopril—Dyspnoea—Methotrexate—hematologic cancer	5.06e-05	5.4e-05	CcSEcCtD
Fosinopril—Somnolence—Methotrexate—hematologic cancer	5.05e-05	5.39e-05	CcSEcCtD
Fosinopril—Dry mouth—Doxorubicin—hematologic cancer	5.01e-05	5.35e-05	CcSEcCtD
Fosinopril—Hypersensitivity—Prednisone—hematologic cancer	5e-05	5.34e-05	CcSEcCtD
Fosinopril—Dyspepsia—Methotrexate—hematologic cancer	5e-05	5.33e-05	CcSEcCtD
Fosinopril—Hypotension—Epirubicin—hematologic cancer	4.96e-05	5.3e-05	CcSEcCtD
Fosinopril—Vomiting—Dexamethasone—hematologic cancer	4.96e-05	5.29e-05	CcSEcCtD
Fosinopril—Vomiting—Betamethasone—hematologic cancer	4.96e-05	5.29e-05	CcSEcCtD
Fosinopril—Confusional state—Doxorubicin—hematologic cancer	4.96e-05	5.29e-05	CcSEcCtD
Fosinopril—Decreased appetite—Methotrexate—hematologic cancer	4.93e-05	5.27e-05	CcSEcCtD
Fosinopril—Rash—Dexamethasone—hematologic cancer	4.92e-05	5.25e-05	CcSEcCtD
Fosinopril—Rash—Betamethasone—hematologic cancer	4.92e-05	5.25e-05	CcSEcCtD
Fosinopril—Anaphylactic shock—Doxorubicin—hematologic cancer	4.91e-05	5.25e-05	CcSEcCtD
Fosinopril—Oedema—Doxorubicin—hematologic cancer	4.91e-05	5.25e-05	CcSEcCtD
Fosinopril—Dermatitis—Betamethasone—hematologic cancer	4.91e-05	5.24e-05	CcSEcCtD
Fosinopril—Dermatitis—Dexamethasone—hematologic cancer	4.91e-05	5.24e-05	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ALB—hematologic cancer	4.9e-05	0.000777	CbGpPWpGaD
Fosinopril—Fatigue—Methotrexate—hematologic cancer	4.89e-05	5.22e-05	CcSEcCtD
Fosinopril—Headache—Dexamethasone—hematologic cancer	4.89e-05	5.21e-05	CcSEcCtD
Fosinopril—Headache—Betamethasone—hematologic cancer	4.89e-05	5.21e-05	CcSEcCtD
Fosinopril—Infection—Doxorubicin—hematologic cancer	4.88e-05	5.21e-05	CcSEcCtD
Fosinopril—Asthenia—Prednisone—hematologic cancer	4.87e-05	5.2e-05	CcSEcCtD
Fosinopril—Pain—Methotrexate—hematologic cancer	4.85e-05	5.18e-05	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.84e-05	5.16e-05	CcSEcCtD
Fosinopril—Shock—Doxorubicin—hematologic cancer	4.83e-05	5.16e-05	CcSEcCtD
Fosinopril—Thrombocytopenia—Doxorubicin—hematologic cancer	4.81e-05	5.14e-05	CcSEcCtD
Fosinopril—Pruritus—Prednisone—hematologic cancer	4.8e-05	5.13e-05	CcSEcCtD
Fosinopril—Insomnia—Epirubicin—hematologic cancer	4.8e-05	5.13e-05	CcSEcCtD
Fosinopril—Tachycardia—Doxorubicin—hematologic cancer	4.8e-05	5.12e-05	CcSEcCtD
Fosinopril—Paraesthesia—Epirubicin—hematologic cancer	4.77e-05	5.09e-05	CcSEcCtD
Fosinopril—Hyperhidrosis—Doxorubicin—hematologic cancer	4.75e-05	5.07e-05	CcSEcCtD
Fosinopril—Dyspnoea—Epirubicin—hematologic cancer	4.74e-05	5.05e-05	CcSEcCtD
Fosinopril—Somnolence—Epirubicin—hematologic cancer	4.72e-05	5.04e-05	CcSEcCtD
Fosinopril—Anorexia—Doxorubicin—hematologic cancer	4.68e-05	5e-05	CcSEcCtD
Fosinopril—Feeling abnormal—Methotrexate—hematologic cancer	4.68e-05	4.99e-05	CcSEcCtD
Fosinopril—Dyspepsia—Epirubicin—hematologic cancer	4.68e-05	4.99e-05	CcSEcCtD
Fosinopril—Diarrhoea—Prednisone—hematologic cancer	4.65e-05	4.96e-05	CcSEcCtD
Fosinopril—Gastrointestinal pain—Methotrexate—hematologic cancer	4.64e-05	4.95e-05	CcSEcCtD
Fosinopril—Nausea—Dexamethasone—hematologic cancer	4.63e-05	4.94e-05	CcSEcCtD
Fosinopril—Nausea—Betamethasone—hematologic cancer	4.63e-05	4.94e-05	CcSEcCtD
Fosinopril—Decreased appetite—Epirubicin—hematologic cancer	4.62e-05	4.93e-05	CcSEcCtD
Fosinopril—Hypotension—Doxorubicin—hematologic cancer	4.59e-05	4.9e-05	CcSEcCtD
Fosinopril—Fatigue—Epirubicin—hematologic cancer	4.58e-05	4.89e-05	CcSEcCtD
Fosinopril—Constipation—Epirubicin—hematologic cancer	4.54e-05	4.85e-05	CcSEcCtD
Fosinopril—Pain—Epirubicin—hematologic cancer	4.54e-05	4.85e-05	CcSEcCtD
Fosinopril—Urticaria—Methotrexate—hematologic cancer	4.51e-05	4.81e-05	CcSEcCtD
Fosinopril—Dizziness—Prednisone—hematologic cancer	4.49e-05	4.79e-05	CcSEcCtD
Fosinopril—Abdominal pain—Methotrexate—hematologic cancer	4.49e-05	4.79e-05	CcSEcCtD
Fosinopril—Body temperature increased—Methotrexate—hematologic cancer	4.49e-05	4.79e-05	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.48e-05	4.78e-05	CcSEcCtD
Fosinopril—Insomnia—Doxorubicin—hematologic cancer	4.44e-05	4.74e-05	CcSEcCtD
Fosinopril—Paraesthesia—Doxorubicin—hematologic cancer	4.41e-05	4.71e-05	CcSEcCtD
Fosinopril—Dyspnoea—Doxorubicin—hematologic cancer	4.38e-05	4.68e-05	CcSEcCtD
Fosinopril—Feeling abnormal—Epirubicin—hematologic cancer	4.38e-05	4.67e-05	CcSEcCtD
Fosinopril—Somnolence—Doxorubicin—hematologic cancer	4.37e-05	4.66e-05	CcSEcCtD
Fosinopril—Gastrointestinal pain—Epirubicin—hematologic cancer	4.34e-05	4.64e-05	CcSEcCtD
Fosinopril—Dyspepsia—Doxorubicin—hematologic cancer	4.33e-05	4.62e-05	CcSEcCtD
Fosinopril—Vomiting—Prednisone—hematologic cancer	4.32e-05	4.61e-05	CcSEcCtD
Fosinopril—Rash—Prednisone—hematologic cancer	4.28e-05	4.57e-05	CcSEcCtD
Fosinopril—Dermatitis—Prednisone—hematologic cancer	4.28e-05	4.57e-05	CcSEcCtD
Fosinopril—Decreased appetite—Doxorubicin—hematologic cancer	4.27e-05	4.56e-05	CcSEcCtD
Fosinopril—Headache—Prednisone—hematologic cancer	4.25e-05	4.54e-05	CcSEcCtD
Fosinopril—Fatigue—Doxorubicin—hematologic cancer	4.24e-05	4.52e-05	CcSEcCtD
Fosinopril—Urticaria—Epirubicin—hematologic cancer	4.22e-05	4.5e-05	CcSEcCtD
Fosinopril—Pain—Doxorubicin—hematologic cancer	4.2e-05	4.49e-05	CcSEcCtD
Fosinopril—Constipation—Doxorubicin—hematologic cancer	4.2e-05	4.49e-05	CcSEcCtD
Fosinopril—Body temperature increased—Epirubicin—hematologic cancer	4.2e-05	4.48e-05	CcSEcCtD
Fosinopril—Abdominal pain—Epirubicin—hematologic cancer	4.2e-05	4.48e-05	CcSEcCtD
Fosinopril—Hypersensitivity—Methotrexate—hematologic cancer	4.18e-05	4.46e-05	CcSEcCtD
Fosinopril—Asthenia—Methotrexate—hematologic cancer	4.07e-05	4.35e-05	CcSEcCtD
Fosinopril—Feeling abnormal—Doxorubicin—hematologic cancer	4.05e-05	4.32e-05	CcSEcCtD
Fosinopril—Nausea—Prednisone—hematologic cancer	4.03e-05	4.31e-05	CcSEcCtD
Fosinopril—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.02e-05	4.29e-05	CcSEcCtD
Fosinopril—Pruritus—Methotrexate—hematologic cancer	4.02e-05	4.29e-05	CcSEcCtD
Fosinopril—Hypersensitivity—Epirubicin—hematologic cancer	3.91e-05	4.18e-05	CcSEcCtD
Fosinopril—Urticaria—Doxorubicin—hematologic cancer	3.9e-05	4.17e-05	CcSEcCtD
Fosinopril—Abdominal pain—Doxorubicin—hematologic cancer	3.88e-05	4.15e-05	CcSEcCtD
Fosinopril—Body temperature increased—Doxorubicin—hematologic cancer	3.88e-05	4.15e-05	CcSEcCtD
Fosinopril—Diarrhoea—Methotrexate—hematologic cancer	3.88e-05	4.14e-05	CcSEcCtD
Fosinopril—Asthenia—Epirubicin—hematologic cancer	3.81e-05	4.07e-05	CcSEcCtD
Fosinopril—Pruritus—Epirubicin—hematologic cancer	3.76e-05	4.01e-05	CcSEcCtD
Fosinopril—Dizziness—Methotrexate—hematologic cancer	3.75e-05	4.01e-05	CcSEcCtD
Fosinopril—Diarrhoea—Epirubicin—hematologic cancer	3.63e-05	3.88e-05	CcSEcCtD
Fosinopril—Hypersensitivity—Doxorubicin—hematologic cancer	3.62e-05	3.86e-05	CcSEcCtD
Fosinopril—Vomiting—Methotrexate—hematologic cancer	3.61e-05	3.85e-05	CcSEcCtD
Fosinopril—Rash—Methotrexate—hematologic cancer	3.58e-05	3.82e-05	CcSEcCtD
Fosinopril—Dermatitis—Methotrexate—hematologic cancer	3.58e-05	3.82e-05	CcSEcCtD
Fosinopril—Headache—Methotrexate—hematologic cancer	3.56e-05	3.8e-05	CcSEcCtD
Fosinopril—Asthenia—Doxorubicin—hematologic cancer	3.53e-05	3.76e-05	CcSEcCtD
Fosinopril—Dizziness—Epirubicin—hematologic cancer	3.51e-05	3.75e-05	CcSEcCtD
Fosinopril—Pruritus—Doxorubicin—hematologic cancer	3.48e-05	3.71e-05	CcSEcCtD
Fosinopril—Vomiting—Epirubicin—hematologic cancer	3.38e-05	3.6e-05	CcSEcCtD
Fosinopril—Nausea—Methotrexate—hematologic cancer	3.37e-05	3.6e-05	CcSEcCtD
Fosinopril—Diarrhoea—Doxorubicin—hematologic cancer	3.36e-05	3.59e-05	CcSEcCtD
Fosinopril—Rash—Epirubicin—hematologic cancer	3.35e-05	3.57e-05	CcSEcCtD
Fosinopril—Dermatitis—Epirubicin—hematologic cancer	3.35e-05	3.57e-05	CcSEcCtD
Fosinopril—Headache—Epirubicin—hematologic cancer	3.33e-05	3.55e-05	CcSEcCtD
Fosinopril—Dizziness—Doxorubicin—hematologic cancer	3.25e-05	3.47e-05	CcSEcCtD
Fosinopril—Nausea—Epirubicin—hematologic cancer	3.15e-05	3.37e-05	CcSEcCtD
Fosinopril—Vomiting—Doxorubicin—hematologic cancer	3.12e-05	3.34e-05	CcSEcCtD
Fosinopril—Rash—Doxorubicin—hematologic cancer	3.1e-05	3.31e-05	CcSEcCtD
Fosinopril—Dermatitis—Doxorubicin—hematologic cancer	3.1e-05	3.3e-05	CcSEcCtD
Fosinopril—Headache—Doxorubicin—hematologic cancer	3.08e-05	3.29e-05	CcSEcCtD
Fosinopril—Nausea—Doxorubicin—hematologic cancer	2.92e-05	3.12e-05	CcSEcCtD
